{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=14",
    "query": {
      "intervention": "SoC",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 1401,
    "total_pages": 141,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SoC&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T08:28:12.754Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05846789",
      "title": "Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Triple Negative Breast Cancer",
        "Estrogen-receptor-low Breast Cancer",
        "ER Positive, HER2 Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "SOC Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab/Tocilizumab Biosimilar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kathy Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 168,
      "start_date": "2024-07-02",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 7,
      "location_summary": "Atlanta, Georgia • Carmel, Indiana • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05846789"
    },
    {
      "nct_id": "NCT05932290",
      "title": "A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Elranatamab",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Weeks and older"
      },
      "enrollment_count": 514,
      "start_date": "2023-06-01",
      "completion_date": "2023-07-12",
      "has_results": true,
      "last_update_posted_date": "2024-10-29",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05932290"
    },
    {
      "nct_id": "NCT06315738",
      "title": "Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ST266 in Infants With Necrotizing Enterocolitis (NEC)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Necrotizing Enterocolitis"
      ],
      "interventions": [
        {
          "name": "ST266",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Noveome Biotherapeutics, formerly Stemnion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": "8 Weeks",
        "sex": "ALL",
        "summary": "2 Weeks to 8 Weeks"
      },
      "enrollment_count": 36,
      "start_date": "2024-08-19",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • New Haven, Connecticut • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06315738"
    },
    {
      "nct_id": "NCT03637478",
      "title": "Enhancing Systems of Care: Supporting Families and Improving Youth Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pediatric Mental Health Services"
      ],
      "interventions": [
        {
          "name": "Enhanced Systems of Care Team",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Cambridge Health Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Years to 17 Years"
      },
      "enrollment_count": 171,
      "start_date": "2017-10-17",
      "completion_date": "2020-09-30",
      "has_results": false,
      "last_update_posted_date": "2020-10-20",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03637478"
    },
    {
      "nct_id": "NCT05911360",
      "title": "A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DTG/3TC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2023-07-07",
      "completion_date": "2026-02-09",
      "has_results": true,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05911360"
    },
    {
      "nct_id": "NCT06859424",
      "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML (Acute Myelogenous Leukemia)",
        "Acute Lymphoid Leukemia (ALL)",
        "Acute Leukemia (Category)",
        "MDS (Myelodysplastic Syndrome)",
        "CML (Chronic Myelogenous Leukemia)",
        "CLL (Chronic Lymphocytic Leukemia)",
        "Prolymphocyctic Leukemia",
        "Chronic Myelomonocytic Leukemia (CMML)",
        "Myeloproliferative Neoplasm (MPN)",
        "Lymphoma",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Conditioning Regimen A",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen B",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen C",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen D",
          "type": "DRUG"
        },
        {
          "name": "Conditioning Regimen E",
          "type": "DRUG"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "PTCy (50 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "PTCy (25 mg/kg D3, D4)",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Post-transplant Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Growth Factors",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Blood Products",
          "type": "PROCEDURE"
        },
        {
          "name": "Supportive Care: Infection Prophylaxis",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Intravenous immune globulin (IVIG)",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Seizure prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Monitoring and management of CRS",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "OTHER"
        },
        {
          "name": "Supportive Care: Prophylaxis against infections",
          "type": "DRUG"
        },
        {
          "name": "Supportive Care: Lipid elevations",
          "type": "OTHER"
        },
        {
          "name": "Study treatment compliance",
          "type": "OTHER"
        },
        {
          "name": "Prohibited Concomitant Therapy",
          "type": "OTHER"
        },
        {
          "name": "Permitted Concomitant Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 358,
      "start_date": "2025-07-25",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06859424"
    },
    {
      "nct_id": "NCT06982820",
      "title": "Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Prism Training",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "GrayMatters Health Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "22 Years to 75 Years"
      },
      "enrollment_count": 170,
      "start_date": "2025-06-25",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island • Houston, Texas",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06982820"
    },
    {
      "nct_id": "NCT01670461",
      "title": "FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "FACE",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard of Care (SOC) Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Maureen Lyon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "14 Years to 90 Years"
      },
      "enrollment_count": 60,
      "start_date": "2009-01",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2019-03-08",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670461"
    },
    {
      "nct_id": "NCT05496868",
      "title": "Add-on Reparixin in Adult Patients With ARDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome, Adult"
      ],
      "interventions": [
        {
          "name": "Reparixin 600mg",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2022-12-06",
      "completion_date": "2025-04-18",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05496868"
    },
    {
      "nct_id": "NCT06972719",
      "title": "Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "BRCA1 Mutation",
        "BRCA2 Mutation"
      ],
      "interventions": [
        {
          "name": "Experimental Arm",
          "type": "BEHAVIORAL"
        },
        {
          "name": "SOC Arm",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "19 Years to 50 Years · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-09-30",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-24T08:28:12.754Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06972719"
    }
  ]
}